SCHEMBL7208003

SCHEMBL7208003

COc1ccccc1COC1CCN(S(=O)(=O)C2CCNCC2(O)C(=O)NO)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
CYP2C19 P33261 2/20 0.41
CYP1A2 P05177 1/20 0.41
TSHR P16473 1/20 0.41
MMP1 P03956 3/20 0.40
ADAM17 P78536 3/20 0.40
GNAI3 P08754 1/20 0.39
USP2 O75604 1/20 0.39
MAPT P10636 1/20 0.38
CYP3A4 P08684 1/20 0.37
MMP2 P08253 1/20 0.37
MMP13 P45452 1/20 0.37
HPGD P15428 1/20 0.37
TACR1 P25103 1/20 0.37
POLB P06746 2/20 0.36
TP53 P04637 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
GRIN2B Q13224 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7205529 0.89 MMP1 (0.45) MMP1ADAM17MMP2MMP13TACR1
SCHEMBL7200507 0.88 MMP13 (0.45) ALDH1A1MMP1ADAM17MMP2MMP13
SCHEMBL7205353 0.88 CARM1 (0.42) MMP1ADAM17MMP2MMP13TACR1
SCHEMBL7202570 0.86 EPHX2 (0.41) ALDH1A1CYP2C19CYP1A2TSHRADAM17
SCHEMBL7200956 0.85 MMP2 (0.46) MMP1ADAM17MMP2MMP13GRIN2B
SCHEMBL7200978 0.85 MMP13 (0.51) MMP1MMP2MMP13
SCHEMBL7202610 0.85 MMP13 (0.42) ALDH1A1MMP1ADAM17MMP2MMP13
SCHEMBL7202583 0.83 ADAM17 (0.40) TSHRMMP1ADAM17USP2MAPT
SCHEMBL7207975 0.83 PKM (0.42) ALDH1A1MMP1ADAM17CYP3A4MMP13
SCHEMBL7208005 0.83 MMP13 (0.42) ALDH1A1MMP1ADAM17MMP2MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 ALDH1A1 1443/4885CYP2C19 2628/4885CYP1A2 1911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.